VAR 200
Focal Segmental Glomerulosclerosis (FSGS) (with expansion potential in Alport syndrome & Diabetic Kidney Disease)
Phase 1Active
Key Facts
Indication
Focal Segmental Glomerulosclerosis (FSGS) (with expansion potential in Alport syndrome & Diabetic Kidney Disease)
Phase
Phase 1
Status
Active
Company
About ZyVersa Therapeutics
ZyVersa Therapeutics is a clinical-stage biopharma founded in 2021, headquartered in Weston, Florida. The company is advancing two distinct, in-licensed platforms: IC 100, a monoclonal antibody targeting the inflammasome adaptor protein ASC to broadly inhibit inflammation, and VAR 200, a cholesterol efflux mediator designed to treat renal diseases by removing pathogenic lipids from kidney cells. ZyVersa's strategy targets large market opportunities in inflammatory and renal diseases, initially focusing on cardiometabolic conditions and orphan renal disease FSGS, with plans for indication expansion and strategic partnerships.
View full company profile